ACL: Alcon Inc - Full Company Report
Enter Ticker:
Alcon, Inc. is the world's leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for sixty years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon's majority shareholder is Nestle, S.A., the world's largest food company. All trademarks noted in this release are the property of Alcon, Inc., with the exception of Ciprodex, which is a registered trademark of Bayer AG and licensed to Alcon, Inc. by Bayer Healthcare AG. Moxifloxacin is licensed to Alcon, Inc. by Bayer Healthcare AG.
General Information
ALCON INC
B??sch 69www.alconinc.com investor.relations@alconlabs.com
Industry
Large Cap Pharma
Sector:
Medical
Fiscal Year End
December
Last Reported Quarter
12/31/09
Next EPS Date
02/11/2010
Price and Volume Information
Zacks Rank
Yesterday's Close
156.11
52 Week High
166.71
52 Week Low
76.03
Beta
1.13
20 Day Moving Average
1,593,263.75
Target Price Consensus
166.22
% Price Change
4 Week
0.68
12 Week
6.86
YTD
-5.01
% Price Change Relative to S&P 500
4 Week
8.31
12 Week
11.18
YTD
-0.85
Share Information
Shares Outstanding (millions)
298.98
Market Capitalization (millions)
46,674.39
Short Ratio
0.87
Last Split Date
N/A
Dividend Information
Dividend Yield
2.33%
Annual Dividend
$3.64
Payout Ratio
0.00
Change in Payout Ratio
0.00
Last Dividend Payout / Amount
NA / $0.00
EPS Information
Current Quarter EPS Consensus Estimate
1.50
Current Year EPS Consensus Estimate
6.71
Estimated Long-Term EPS Growth Rate
11.80
Next EPS Report Date
02/11/2010
Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)
2.17
30 Days Ago
2.00
60 Days Ago
2.00
90 Days Ago
2.00
Fundamental Ratios
P/E
Current FY Estimate:
21.23
Trailing 12 Months:
23.62
PEG Ratio
1.81
EPS Growth
vs. Previous Year
33.59%
vs. Previous Quarter
-11.86%
Sales Growth
vs. Previous Year
5.86%
vs. Previous Quarter:
-3.76%
Price Ratios
Price/Book
8.64
Price/Cash Flow
23.33
Price / Sales
-
ROE
12/31/09
-
09/30/09
39.78
06/30/09
39.16
ROA
12/31/09
-
09/30/09
25.44
06/30/09
24.31
Current Ratio
12/31/09
-
09/30/09
2.70
06/30/09
2.43
Quick Ratio
12/31/09
-
09/30/09
2.37
06/30/09
2.12
Operating Margin
12/31/09
-
09/30/09
31.63
06/30/09
30.01
Net Margin
12/31/09
-
09/30/09
35.64
06/30/09
33.82
Pre-Tax Margin
12/31/09
-
09/30/09
35.64
06/30/09
33.82
Book Value
12/31/09
-
09/30/09
18.07
06/30/09
16.00
Inventory Turnover
12/31/09
-
09/30/09
2.43
06/30/09
2.44
Debt-to-Equity
12/31/09
-
09/30/09
0.01
06/30/09
0.01
Debt to Capital
12/31/09
-
09/30/09
1.10
06/30/09
1.18
Sponsored Links 
1.35